EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pathophysiology of Doxorubicin-Mediated Cardiotoxicity

Roberto Arrigoni iD, Emilio Jirillo, Carlo Caiati iD

Toxics · 05.04.2025 · 13 (4) · 277

DOI: 10.3390/toxics13040277 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxics, online erschienen am 05.04.2025. Verfasst von Roberto Arrigoni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council, 70124 Bari, Italy. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) is used for the treatment of various malignancies, including leukemias, lymphomas, sarcomas, and bladder, breast, and gynecological cancers in adults, adolescents, and children. However, DOX causes severe side effects in patients, such as cardiotoxicity, which encompasses heart failure, arrhythmia, and myocardial infarction. DOX-induced cardiotoxicity (DIC) is based on the combination of nuclear-mediated cardiomyocyte death and mitochondrial-mediated death. Oxidative stress, altered autophagy, inflammation, and apoptosis/ferroptosis represent the main pathogenetic mechanisms responsible for DIC. In addition, in vitro and in vivo models of DIC sirtuins (SIRT), and especially, SIRT 1 are reduced, and this event contributes to cardiac damage. In fact, SIRT 1 inhibits reactive oxygen species and NF-kB activation, thus improving myocardial oxidative stress and cardiac remodeling. Therefore, the recovery of SIRT 1 during DIC may represent a therapeutic strategy to limit DIC progression. Natural products, i.e., polyphenols, as well as nano formulations of DOX and iron chelators, are other potential compounds experimented with in models of DIC. At present, few clinical trials are available to confirm the efficacy of these products in DIC. The aim of this review is the description of the pathophysiology of DIC as well as potential drug targets to alleviate DIC.

Schlagwörter

Stichwörter der Autor:innen

cardiotoxicitydoxorubicinferroptosisinflammationoxidative stresssirtuins

Autor:innen und Institutionen

  • Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council, 70124 Bari, Italy.
  • Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
  • Unit of Cardiovascular Diseases, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.

ORCID-Profile: Roberto Arrigoni, Carlo Caiati

Zitieren

APA

Arrigoni, R., Jirillo, E., & Caiati, C. (2025). Pathophysiology of Doxorubicin-Mediated Cardiotoxicity. Toxics, 13(4), 277. https://doi.org/10.3390/toxics13040277

Vancouver

Arrigoni R, Jirillo E, Caiati C. Pathophysiology of Doxorubicin-Mediated Cardiotoxicity. Toxics. 2025;13(4):277. doi:10.3390/toxics13040277

BibTeX
@article{Arrigoni2025,
  author = {Arrigoni, Roberto and Jirillo, Emilio and Caiati, Carlo},
  title = {Pathophysiology of Doxorubicin-Mediated Cardiotoxicity},
  journal = {Toxics},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {277},
  doi = {10.3390/toxics13040277}
}
Kostenlos starten →